Search
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
The Angels Initiative – F.A.S.T.
The Angels initiative, stroke symptoms, giving life a chance, optimizing stroke care
Complications of Diabetic Retinopathy
Both Diabetic Macular Edema and Ischemia are maculopathies, they specifically affect the macula, responsible for high visual acuity.
Leading experts shed light on importance of establishing dedicated stroke management centers
Leading experts shed light on importance of establishing dedicated stroke management centers across healthcare facilities
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
10 things you should know about rabies
10 things you should know about rabies
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Why today’s depression trials demand smart new approaches
Dr. Vikas Mohan Sharma announces the first of its kind decentralized clinical trial in depression
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Guardians for health
A global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guidelines.
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
The ‘GPP Summit, discussed latest research and advances in the management of GPP to help improve patient outcomes across Saudi Arabia, and the United Arab Emirates.
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Cairo Tower lights up in Blue for World Diabetes Day
Cairo Tower lights up in Blue for World Diabetes Day
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
ProZinc
Protamine Zinc
Prevention of Schizophrenia
Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D